Skip to content
My WebMD Sign In, Sign Up

Ulcerative Colitis Health Center

Font Size

Remicade Treats Ulcerative Colitis

Better Results Than With Fake Drug, Researchers Report
By
WebMD Health News
Reviewed by Louise Chang, MD

Dec. 7, 2005 -- The rheumatoid arthritis drug Remicade may help treat moderate-to-severe ulcerative colitis, a new study shows.

WebMD first reported the news in May, when findings were presented at a medical conference. Now, more details appear in The New England Journal of Medicine.

The researchers included Paul Rutgeerts, MD. He works in Leuven, Belgium, at the University Hospital Gasthuisberg.

Ulcerative colitis is an inflammatory bowel disease that primarily affects the colon and rectum with inflammation and ulcers leading to bleeding and abdominal pain. The disease generally follows a course of flare-ups that can be difficult to manage. In some circumstances, surgery may be necessary to remove the affected area.

About Remicade

Remicade is a biologic drug given by infusion. It targets the immune system and blocks an inflammatory chemical called tumor necrosis factor (TNF). Besides rheumatoid arthritis, it's also used to treat Crohn's disease (another inflammatory bowel disease) and ankylosing spondylitis, a form of arthritis.

Remicade was recently tested in two studies, which included 728 patients with moderate to severe ulcerative colitis. The patients' colitis hadn't responded to other drugs.

In each study, patients were split into three groups. One group got a low Remicade dose (5 milligrams). Another got a higher dose of Remicade (10 milligrams). A third group got a fake drug containing no medicine (placebo).

Patients got three treatments within six weeks, followed by less-frequent maintenance doses for several months.

Studies' Results

In both studies, more people taking Remicade showed improvement in ulcerative colitis symptoms than did those who got the fake drug.

The first study lasted for about a year. By eight weeks, 64% of patients taking the low dose of Remicade and 69% of those taking the higher dose met the researchers' target for reduced ulcerative colitis symptoms. When it finished, more than four in 10 patients taking Remicade met the goal. In the placebo group, 20% showed the same response.

The second study was shorter, lasting for 30 weeks. By eight weeks, 69% of patients taking the low Remicade dose and 61% of those taking the higher dose met the goal. That's compared with 37% of the placebo group. At 30 weeks, both study groups showed better response in those patients taking Remicade.

The results show that TNF plays a role in ulcerative colitis and makes a good treatment target, write Rutgeerts and colleagues.

Remicade's Side Effects

Reports of adverse effects came from similar percentages of patients taking Remicade or the placebo.

However, the Remicade groups had slightly more cases of serious infections, lupus-like reactions, and neurologic diseases, write the researchers.

Those cases included:

  • 1 patient taking Remicade who had a lupus-like reaction
  • 16 taking Remicade who had serious infections (compared with six taking placebo)
  • 1 taking Remicade who had tuberculosis
  • 1 taking Remicade who died after getting a type of pneumonia

Today on WebMD

basket of vegetables
Article
IBD Overview Slideshow
Slideshow
 
Ulcerative Colitis Managing Flares
Slideshow
what is ibs
Article
 

Supplements UC
Video
Ulcerative Colitis Health Check
Tool
 
Ulcerative Colitis Diet
Slideshow
Ulcerative Colitis Diet Yogurt
Article
 

Ulcerative Colitis Surgery
Slideshow
Ulcerative Colitis Medications
Article
 
Exercising When You Have A GI Disorder
Article
Picture Of The Intestines
Image Collection
 

WebMD Special Sections